{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:45:31Z","timestamp":1753879531019,"version":"3.41.2"},"reference-count":26,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2018,2,27]],"date-time":"2018-02-27T00:00:00Z","timestamp":1519689600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Scand J Immunol"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Taking into consideration the multiparametric nature of systemic lupus erythematosus (<jats:styled-content style=\"fixed-case\">SLE<\/jats:styled-content>), the severity and variability of symptoms and the lack of effective therapeutic approaches, this study took advantage of the recently described role of soluble major histocompatibility complex class <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> (<jats:styled-content style=\"fixed-case\">sMHCII<\/jats:styled-content>) molecules in maintaining tolerance to the organism and attempted to apply <jats:styled-content style=\"fixed-case\">sMHCII<\/jats:styled-content> proteins as a treatment to murine <jats:styled-content style=\"fixed-case\">SLE<\/jats:styled-content> experimental models in\u00a0vitro as well as in\u00a0vivo. After breaking tolerance to <jats:styled-content style=\"fixed-case\">DNA<\/jats:styled-content> in\u00a0vitro, which was accompanied by development of specific anti\u2010ds<jats:styled-content style=\"fixed-case\">DNA<\/jats:styled-content> antibodies, syngeneic or allogeneic <jats:styled-content style=\"fixed-case\">sMHCII<\/jats:styled-content> molecules, purified from healthy mouse serum, could significantly reduce the specific antibody levels and drive the system towards immunosuppression, as assessed by specific marker analysis on T cells and cytokine production by flow cytometry and <jats:styled-content style=\"fixed-case\">ELISA<\/jats:styled-content>, respectively. The in\u00a0vivo experimental model consisted of pristane\u2010induced <jats:styled-content style=\"fixed-case\">SLE<\/jats:styled-content> symptoms to <jats:styled-content style=\"fixed-case\">BALB<\/jats:styled-content>\/c mice, which developed maximal levels of anti\u2010ds<jats:styled-content style=\"fixed-case\">DNA<\/jats:styled-content> 2\u00a0months after pristane inoculation. Syngeneic or allogeneic <jats:styled-content style=\"fixed-case\">sMHCII<\/jats:styled-content> administration could alleviate pristane\u2010induced symptoms, significantly decrease specific anti\u2010ds<jats:styled-content style=\"fixed-case\">DNA<\/jats:styled-content> antibody production and develop immunosuppression to the host, as manifested by increase of <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>4\u00a0+\u00a0<jats:styled-content style=\"fixed-case\">CTLA<\/jats:styled-content>\u20104\u00a0+\u00a0 and <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>4\u00a0+\u00a0<jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>25\u00a0+\u00a0 cell populations in the spleen. Thus, the results presented in this study introduced the ability of <jats:styled-content style=\"fixed-case\">sMHCII<\/jats:styled-content> proteins to suppress specific autoantigen response, opening new areas of research and offering novel therapeutic approaches to <jats:styled-content style=\"fixed-case\">SLE<\/jats:styled-content> with expanding features to other autoimmune diseases.<\/jats:p>","DOI":"10.1111\/sji.12644","type":"journal-article","created":{"date-parts":[[2018,2,7]],"date-time":"2018-02-07T15:30:22Z","timestamp":1518017422000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Soluble <scp>MHC<\/scp> class <scp>II<\/scp>\u2010driven therapy for a systemic lupus erythematosus murine experimental in\u00a0vitro and in\u00a0vivo model"],"prefix":"10.1111","volume":"87","author":[{"given":"K.","family":"Bakela","sequence":"first","affiliation":[{"name":"Laboratory of Immunology Department of Biology University of Crete Heraklion Crete Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Dimakopoulou","sequence":"additional","affiliation":[{"name":"Laboratory of Immunology Department of Biology University of Crete Heraklion Crete Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Batsou","sequence":"additional","affiliation":[{"name":"Laboratory of Immunology Department of Biology University of Crete Heraklion Crete Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Manidakis","sequence":"additional","affiliation":[{"name":"Laboratory of Immunology Department of Biology University of Crete Heraklion Crete Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4762-119X","authenticated-orcid":false,"given":"I.","family":"Athanassakis","sequence":"additional","affiliation":[{"name":"Laboratory of Immunology Department of Biology University of Crete Heraklion Crete Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,2,27]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2010.10.006"},{"key":"e_1_2_7_3_1","first-page":"321359","article-title":"Serology of lupus erythematosus: correlation between immunopathological features and clinical aspects","volume":"2014","author":"Cozzani E","year":"2014","journal-title":"Autoimmune Dis"},{"key":"e_1_2_7_4_1","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/acr.22591","article-title":"Diagnosis, monitoring, and treatment of systemic lupus erythematosus: a systemic review of clinical practice guidelines","volume":"67","author":"Tunnicliffe DJ","year":"2015","journal-title":"Arthritis Care Res"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gene.6364338"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2004.06.017"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0608299104"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12360"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2011.07.029"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2005.02245.x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0198-8859(98)00122-0"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-0039.2000.560506.x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0198-8859(02)00431-7"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0198-8859(98)00071-8"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0198-8859(00)00123-3"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2003.55"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.11.031"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0001-2815.2004.00201.x"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10524"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200636041"},{"key":"e_1_2_7_21_1","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.imbio.2009.04.005","article-title":"Serum\u2010derived MHC class II molecules: potent regulators of the cellular and humoral immune response","volume":"215","author":"Marios\u2010Frankiskos S","year":"2010","journal-title":"Immunobiology"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.180.6.2341"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.24.10934"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/271694"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/0300985810370005"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/227680a0"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/23.24.5087"}],"container-title":["Scandinavian Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fsji.12644","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/sji.12644","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T15:21:50Z","timestamp":1695568910000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/sji.12644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,27]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1111\/sji.12644"],"URL":"https:\/\/doi.org\/10.1111\/sji.12644","archive":["Portico"],"relation":{},"ISSN":["0300-9475","1365-3083"],"issn-type":[{"type":"print","value":"0300-9475"},{"type":"electronic","value":"1365-3083"}],"subject":[],"published":{"date-parts":[[2018,2,27]]},"assertion":[{"value":"2018-01-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-01-31","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-02-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e12644"}}